Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics Inc (NQ: PLRX )

27.65 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 186
Open 27.65
Bid (Size) 17.06 (1)
Ask (Size) 29.78 (1)
Prev. Close 27.65
Today's Range 27.65 - 27.65
52wk Range 3.965 - 36.64
Shares Outstanding 35,937,937
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue without modification and proceed to evaluate 320 mg dose 
From Pliant Therapeutics, Inc.
Via Globe NewsWire
9 Analysts Have This to Say About Pliant Therapeutics
 
Via Benzinga

Performance

YTD
+45.53%
+45.53%
1 Month
-9.14%
-9.14%
3 Month
+46.53%
+46.53%
6 Month
+25.57%
+25.57%
1 Year
+265.74%
+265.74%

More News

Read More
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Why Pliant Therapeutics Stock Is Skyrocketing This Week
Via The Motley Fool
Expert Ratings for Pliant Therapeutics
Via Benzinga
An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50%
Via Investor's Business Daily
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Via Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Via MarketBeat
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
Via Benzinga
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Dow, Nasdaq Boasting Triple-Digit Midday Lead
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 300 Points; Crude Oil Up 1%
Via Benzinga
Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis
Via Spotlight Growth
US Stocks Mostly Higher; Synchrony Financial Earnings Top Views
Via Benzinga
Why Is Xylem (XYL) Stock Down 9% Today
Via InvestorPlace
Why Is Ryvyl (RVYL) Stock Is On the Move Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.